Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO – Get Rating) – Research analysts at Northland Capmk issued their Q2 2023 EPS estimates for Cardio Diagnostics in a report issued on Monday, May 22nd. Northland Capmk analyst C. Byrnes forecasts that the company will post earnings of ($0.21) per share for the quarter. Northland Capmk also issued estimates for Cardio Diagnostics’ Q3 2023 earnings at ($0.21) EPS, Q4 2023 earnings at ($0.21) EPS, FY2023 earnings at ($0.75) EPS, FY2024 earnings at ($0.75) EPS, FY2025 earnings at ($0.70) EPS and FY2026 earnings at ($0.55) EPS.
Separately, Northland Securities started coverage on shares of Cardio Diagnostics in a research report on Monday. They set an “outperform” rating for the company.
Cardio Diagnostics Stock Performance
Institutional Trading of Cardio Diagnostics
Several institutional investors have recently added to or reduced their stakes in the business. Bank of America Corp DE purchased a new stake in Cardio Diagnostics during the first quarter valued at about $59,000. Susquehanna International Group LLP purchased a new stake in shares of Cardio Diagnostics during the fourth quarter worth about $26,000. State Street Corp purchased a new stake in shares of Cardio Diagnostics during the first quarter worth about $163,000. Finally, Geode Capital Management LLC purchased a new stake in shares of Cardio Diagnostics during the first quarter worth about $290,000. 77.29% of the stock is currently owned by hedge funds and other institutional investors.
About Cardio Diagnostics
Cardio Diagnostics Holdings, Inc, a biotechnology company, develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks. The company was founded in 2017 and is headquartered in Chicago, Illinois.
- Get a free copy of the StockNews.com research report on Cardio Diagnostics (CDIO)
- Toll Brothers Rises On Results, But The Roof Is In Place
- It’s Time To Try On VF Corporation’s 6% Yield
- PetCo Management Getting it Right? Earnings Beat Says Yes
- Axcelis Stock In Buy Range After Chart Breakout, Strong Guidance
- Kohl’s 10% Yield Comes Into High Fashion
Receive News & Ratings for Cardio Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardio Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.